Peter Farina
Executive in Residence @ Canaan Partners
North Salem, United States
Peter Farina is a Series B investor at Canaan Partners in North Salem focused on Sensor and Medical. Peter Farina is based out of North Salem, New York and is the Executive in Residence of Canaan. Peter previously worked at Developing World Cures as a CEO. Peter Farina attended the University at Buffalo.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Peter Farina invests in
Stages Peter Farina invests in
Countries Peter Farina invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Sensor 1 (50%)
- Medical 1 (50%)
- Biotechnology 1 (50%)
- Health Diagnostics 1 (50%)
Stage
- Series B 1 (50%)
- Series C 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
|
Sample6 is a synthetic-biology based bacteria diagnostic system capable of enrichment-free detection. Its technology detects as low as 1CFU/ml in just 4 hours.Its proprietary Bioillumination Platform was developed by Professor Tim Lu (MIT) and Dr. Michael Koeris in the lab of Professor James Collins at the Howard Hughes Medical Institute andBoston University. The platform allows for the engineering of bioparticles that target and “light up” specific unwanted bacteria—or specific groups of bacterial species. They couple this capability with highly sensitive sensor technology that detects low levels of pathogens to see results in minutes—right on-site—with no laboratory required.Sample6′s mission is to improve the health and safety of global consumers by building integrated systems that quickly and easily detect harmful and unwanted bacteria. They see applications in food production, retailing, healthcare, and beyond—anywhere humans and bacteria intersect. | $12.7M / Series C / Aug 22, 2016 | |
|
|
Sample6 is a synthetic-biology based bacteria diagnostic system capable of enrichment-free detection. Its technology detects as low as 1CFU/ml in just 4 hours.Its proprietary Bioillumination Platform was developed by Professor Tim Lu (MIT) and Dr. Michael Koeris in the lab of Professor James Collins at the Howard Hughes Medical Institute andBoston University. The platform allows for the engineering of bioparticles that target and “light up” specific unwanted bacteria—or specific groups of bacterial species. They couple this capability with highly sensitive sensor technology that detects low levels of pathogens to see results in minutes—right on-site—with no laboratory required.Sample6′s mission is to improve the health and safety of global consumers by building integrated systems that quickly and easily detect harmful and unwanted bacteria. They see applications in food production, retailing, healthcare, and beyond—anywhere humans and bacteria intersect. | $13.5M / Series B / Oct 09, 2013 |
Co-Investors
About Canaan Partners
Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $5B under management, a diversified fund and over 190 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 30 years. Canaan’s focus areas include fintech, enterprise/cloud,marketplaces, frontier tech, biopharma, digital health, and medtech.
Canaan Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Deepak Kamra
General Partner
|
|||
|
Peter Farina
Executive in Residence
|
|||
|
Bob Williams
VC In Residence
|
|||
|
Brendan Dickinson
General Partner
|
|||
|
Brenton Ahrens
General Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Peter Farina invest in?
Peter Farina invests primarily in Sensor, Medical and Biotechnology startups, most often at Series B and Series C stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Peter Farina?
Public channels for Peter Farina include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Peter Farina last invest?
The most recent investment recorded for Peter Farina closed in Aug 2016. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!